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Background: Malignant gliomas are a fatal disease that despite extensive research in the 
field, are still poorly understood. The primary form of treatment has been tumor reduction 
using a combination of radiotherapy, chemotherapy and surgery, but median survival of 
adult and pediatric patients is about 2 years. Thus, it is imperative to understand this disease 
and develop therapies that can eradicate these infiltrative tumor cells without having 
significant toxicity to the normal functioning of the brain.  
CRISPR-interference (Clustered Regularly Interspaced Short Palindromic Repeats; 
CRISPRi) screens have identified long noncoding RNAs (lncRNAs) that may potentiate 
the effects of radiation in gliomas. lncRNAs exhibit highly cell type-specific expression 
and function, making these attractive targets for potential cancer therapies. This class of 
transcript is poorly studied thus far as a potential therapeutic target.  
Current models of human glioma fall short of recapitulating the tumor 
microenvironment, and therefore, make testing potential therapies difficult. For example, 
because CTC338M12.4 (lncGRS-1), a potential glioma therapeutic target, is only 
expressed in primates, it would be time-consuming and expensive to perform studies on 
genetically-engineered mouse models.  
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Objectives:  1) To explore the role of lncGRS-1 as a glioma-specific therapeutic target and 
in the p53-mediated DNA damage response, 2) To build upon a new experimental model 
system that can better represent the characteristics of human glioma.  
Methods: Project One: I performed knockdown assays of lncGRS-1 and analyzed levels 
p53 and p21 levels by Western Blot analysis. I also identified presence of phospho-53 
binding protein (P53BP1) and γ H2AX by immunohistochemistry. Finally, I performed 
double knockdowns of lncGRS-1 and p53 to study the effect on cell proliferation. 
Project Two: I generated mature brain organoids (MBOs) of 10,000 cells comprised of 
astrocytes, neurons, and pediatric glioma cells. Tumor burden of glioma cells growing in 
the MBOs was assessed over a period of 10 days and quantified with ImageJ. I generated 
MBOs of 60,000 cells comprised of astrocytes, neurons, pediatric glioma cells, and two 
different types of endothelial cells labeled with calcein. Organoids were placed in three 
different media compositions and combinations of epithelial growth factor and basic 
fibroblast growth factor and followed for 8 days.  
Results: Project One: lncGRS-1 knockdown reduced both p53 and p21 levels. P53BP1 
levels increased in the presence of radiation and lncGRS-1 knockdown, as well as with 
knockdown alone. γ-H2AX levels were not impacted significantly by lncGRS-1 
knockdown. U87 glioma cells had decreased proliferation with p53 and lncGRS-1 double 
knockdown than with lnGRS-1 knockdown alone. Project Two: Introducing EGF/FGF-2 
at 10 ng/mL concentration produced MBOs with tumors that did not overtake the organoid 
within 10 days. Cortical organoid media appeared to be the best media composition to 
support MBOs comprised of endothelial cells, astrocytes, neurons, and glioma cells.   
	
	 viii 
Conclusions: Project One: Our results suggest that lncGRS-1 plays a role in the DNA 
damage response by modifying a cell’s ability to pass cell cycle checkpoints.  Project Two: 
I generated mature brain organoids comprised of 4 different cell types – astrocytes, 
neurons, endothelial cells, and glioma cells. Furthermore, I identified a media composition 
(cortical organoid media) that allowed for all cell types to survive for at least a one week.  
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INTRODUCTION PROJECT ONE 
lncRNAs as potential therapeutic targets for human gliomas 
Malignant Gliomas are highly lethal brain tumors that are difficult to treat due to 
their infiltrative nature.  
Malignant gliomas are a fatal disease, but despite many years of research, glioma 
development and progression remains poorly understood. For example, current treatment 
protocols for adult glioblastomas involve tumor resection when possible, radiotherapy, and 
chemotherapy (Stupp et al., 2009). Advances in biotechnologies such as MRI-guided 
neuro-navigation and fluorescence-guided surgery (Stummer et al., 2006) increase 
precision of tumor resection. Although gliomas cannot be completely removed surgically, 
this approach allows for increased survival in patients (Lacroix et al., 2001). Despite this, 
patients diagnosed with glioblastomas have a median survival of about 13.8 months 
following surgery (Grabowski et al., 2014).  
Outcomes in children with diffuse intrinsic pontine glioma (DIPG), where surgery 
is not possible due to the tumor’s location in the pons, share similar dismal outlooks, with 
less than ten percent of patients surviving beyond two years following diagnosis (Hargrave 
et al., 2006). DIPG cases make up about 80% of brainstem tumors in children and the tumor 
migrates through the pons while mingling with the neurons and glial cells (Helton et al., 
2008), the location of critical neural nuclei for essential body functions. Hence, tumor 
resection is not possible. Although radiotherapy has been the standard of care treatment 
following initial diagnosis in controlling tumor growth, the disease can progress within a 
year post-irradiation (Turner et al., 2007).  
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Even post-treatment, due to the infiltrative nature of gliomas, tumor cells have 
already invaded adjacent brain tissue and have tumorigenic potential (Taal et al., 2008). In 
some cases, even following aggressive treatment protocols, gliomas will still return (Taal 
et al., 2008). A retrospective study showed that despite treating newly diagnosed 
glioblastoma patients with radiotherapy and temozolomide, 12 of the 18 patients developed 
new clinical indications following treatment (Taal et al., 2008).   
It is imperative to understand this disease and develop therapy that can eradicate 
these cells without having significant toxicity to the normal functioning of the brain. 
 
CRISPRi-based platform has been utilized to target and identify function of several 
thousands of lncRNAs.  
The human genome produces tens of thousands of long noncoding RNAs 
(lncRNAs) (Cabili et al., 2011), defined as transcripts longer than 200 nucleotides that 
resemble mRNA in that they can be spliced and polyadenylated but do not encode for 
proteins (Quinn & Chang, 2016). Due to their highly cell-type specific expression, 
lncRNAs present an interesting target for targeted cancer therapies (Zhou et al., 2007). 
Rapid evaluation of these transcripts as a feasible class of targets for therapy requires the 
use of systematic functional screens.   
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology 
has been valuable to the classification of genes – coding and noncoding – into their roles 
for specific cellular function (Liu et al., 2017). For example, research from the Lim Lab 
developed a CRISPRi platform targeting tens of thousands of lncRNAs. The system 
	
3 
identified 499 lncRNAs involved in cellular growth, of which 89% were cell-type specific 
(Liu et al., 2017). The CRISPRi system requires coexpression of catalytically “dead” Cas9 
protein and a single guide RNA (sgRNA) complementary to the locus of interest (Figure 
1). Cas9-sgRNA will complex and the sgRNA will guide this complex to the target site. 
This prevents RNA polymerase from continuing transcription of that gene (Fig. 1, (Larson 
et al., 2013)). As a follow up to this study, previous investigators from the Lim lab also 
used CRISPRi to develop a radiation modifier screen for 5689 lncRNA loci, identifying 33 
lncRNA targets with radiation sensitizing function (Liu et al., 2017). Of these, 9 were 






The first of these hits, lncGRS-1 (CTC-338M12.4 located on chromosome 5 q35.3), 
encodes spliced, poly-adenylated transcripts from chromosome 5. To validate lncGRS-1 as 
a potential therapeutic target, locked nucleic acid antisense oligonucleotides instead of 
CRISPRi were used, as CRISPR in any form is not yet allowed to be used as treatment in 
humans.  
Figure 1. CRISPRi uses dCas9-KRAB to repress genetic targets. 
Representation of dCas9-KRAB interacting with sgRNAs and DNA (in red). 
Parts of the gRNA-dCas9-KRAB complex that interact with DNA sequence 




Antisense oligonucleotides (ASOs) allow for modulation of RNA processing and 
protein synthesis in in vitro and in vivo models. ASOs can affect gene expression by many 
mechanisms. For example, they can degrade complementary RNAs by binding to the target 
RNA sequence and causes its degradation (Wu et al., 2004). ASOs thus represent a new 
class of potential therapeutics against various diseases. The FDA has approved using ASOs 
to treat Duchenne muscular dystrophy. This ASO works by skipping exon 51 of the DMD 
gene (Havens & Hastings, 2016).  
 
The DNA damage response is dysregulated in cancer cells.   
The DNA Damage Response (DDR) in all cells is activated in response to nicks 
and lesions in DNA due to exogenous or endogenous insults (Lindahl & Nyberg, 1972). 
The response allows for cells to maintain integrity of the genome.  
As DNA injury accumulates over time, the cell progresses towards senescence and 
eventual apoptosis (Di Micco et al., 2006, Herbig et al., 2004). This progression serves as 
a check on mitosis and prevents cells with too much accumulated damage from continuing 
to replicate (Bartkova et al., 2005). Studies show that p53 prevents oncogenic 
transformation (Gorgoulis et al., 2005) and is also involved in the clearance of DNA-
damaged cells by involving the immune system (Xue et al., 2007). Furthermore, p53 
regulates genes involved in aging of the cell. TP53 function is inactivated or lost in about 
50% of human cancers.  
The goal of project one was to study how lncGRS-1 knockdown impacts cell cycle 




Mature Brain Organoids as a Novel Platform to Study Human Glioma Progression 
2D culture models of malignant glioma cannot completely recapitulate this complex 
disease.  
Great strides in biomedical research have allowed researchers to understand glioma 
growth and proliferation as well as evaluate potential therapies’ efficacy prior to allowing 
these therapies to move into clinical trial phase. Targeted molecular therapy research 
focuses on inhibiting various tyrosine kinase receptors such as EGFR (epithelial growth 
factor receptor), VEGFR (vascular endothelial growth factor receptor), and PDGFR 
(platelet-derived growth factor receptor) (Bartkova et al., 2005). Some of these studies have 
successfully generated drugs that could be clinically tested (Rich et al., 2004). A major 
challenge in translating drug development from bench to bedside is testing the therapy in 
an environment that more closely recapitulates in vivo tumor conditions. Currently, in vitro 
and in vivo studies have been the mainstays of understanding tumor growth and 
proliferation and evaluating therapeutic efficacy.  
 Two-dimensional (2D) cell culture allows for researchers to control and manipulate 
the environment in which tumors grow, such as defining media compositions or 
introducing molecules to activate or repress genes of interest. Therefore, 2D culture is a 
high-throughput and cost-efficient way to gain important preliminary information about 
human diseases such as glioblastomas. 
 Although 2D cultures give researchers the ability to control many factors involved 
in tumor growth and progression, this model cannot truly mimic the in vivo environment. 
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For example, 2D cultured cells behave differently than they do in tissue in vivo (Pampaloni 
et al., 2007). Furthermore, the in vitro environment only contains one cell type, so we 
cannot evaluate drug toxicity to cancer cells versus normal cells. As a result, it is difficult 
to assess the efficacy of a potential therapy in 2D culture.  
 
In vivo studies come close to modeling the tumor environment of gliomas, but still fall 
short.  
 Genetically engineered mouse models (GEMMs) have been utilized to study the 
invasive growth of glioblastomas as well as drug toxicity and efficacy in 
immunocompetent species (Lenting et al., 2017). However, these models lack intra-
tumoral heterogeneity that has been shown to exist in gliomas, which was established by 
genetic analyses of many biopsies of the same tumor as well as later at the single-cell level 
by single-cell RNA-seq (Kim et al., 2015). We thus face a similar issue as in 2D cultures 
of lack of heterogeneity, meaning that testing potential therapies in GEMMs may not lead 
to similar results as in human testing.  
 One may also directly surgically implant human GBM cells into immunodeficient 
mice, called a patient-derived xenograft (PDX) model. Gliomas can be introduced in two 
ways in PDX models - heterotopic (subcutaneous flank) and orthotopic (intracranial) 
xenografts (Joo et al., 2013). However, the PDX model has its shortcomings as well. 
Continuously culturing the tumor lines to establish GBM cell lines can lead to alterations 
in the genome and therefore loss of phenotypic characteristics of the original GBM line, 
leading to loss of the original tumor properties (Allen et al., 2016, p. 87). Although human 
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GBM cells can be surgically transplanted into the brain of immunodeficient mice and 
human tumors can grow invasively in mouse tissue, the process is time-consuming and 
cost-inefficient. Hence, PDX models present a low-throughput method to understand 




Table 1. Comparison of two widely used models to study human gliomas. Although 
2D cultures are high throughput and cost-efficient, they cannot model glioma invasiveness 
or assess drug toxicity to normal cells. On the other hand, genetically engineered mouse 
models and patient-derived xenografts, although able to assess drug toxicity and model 
glioma invasiveness, are low throughput and cost-inefficient. Thus, it is important to find 
an effective way to study and treat human gliomas that covers all of these important factors. 
 
The shortcomings of the traditional models for studying this fatal disease therefore 
present a significant challenge in translating therapies from the laboratory bench to bedside. 
It is imperative to develop a model that will not only recapitulate the tumor environment 
to study how gliomas progress, but also one that can effectively assess upcoming drugs’ 
consequence on the tumor micro-environment.  
 
 
mBrain Organoids are a novel platform for studying neural tissues comprised of 
mature cell types.  
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Human organoids provide a new platform in studying cell biology. An organoid is 
a miniature 3D representation of an organ, composed of different cell types that can self-
organize and emulate the conditions representative of the tissue microenvironment. 
Different organoid models have been described, including intestinal organoids (Múnera & 
Wells, 2017), hepatocyte organoids (Guye et al., 2016), pulmonary organoids (Dye et al., 
2015), and cerebral organoids (Cakir et al., 2019).  
 Induced pluripotent stem cell technology can be used to generate cerebral organoids 
allowing for the study of embryonic neural development and complex neural diseases 
(Figure 2A) (Lancaster & Knoblich, 2014). Although embryonic brain organoids (EBO) 
present a sufficient 3D model for studying genetic mutations involved in glioblastomas 
(Bian et al., 2018), they do not recapitulate the mature brain tissue of glioma patients’ brain. 
Gliomas almost never arise pre-natally; therefore, a cerebral organoid model containing 
mature neural tissue, including astrocytes, neurons, and various other cell types, is 
necessary to evaluate drugs and study important tumor characteristics. Other studies have 
generated glioblastoma organoids (tumor organoids) that do not contain any normal cells 
(Jacob et al., 2020). We cannot assess drug toxicity to mature brain tissue using the EBO 
model or the GBM tumor organoid model, because they do not contain a vascular supply, 




Figure 2. Embryonic Brain Organoids and Glioblastoma Organoids. Figure 
representing the differences between EBOs and MBOs. (A) EBOs are comprised of 
immature, proliferative neural progenitor cells and contain few astrocytes, which are the 
main cell population present in the adult brain, where gliomas arise. (B) Tumor organoids 
do not contain any normal cells and therefore cannot model invasive growth. 
 
Astrocytes are the most abundant cell type in the mature human brain, 
outnumbering neurons by over five-fold (Sofroniew & Vinters, 2010). It is clear that these 
cells are able to respond to many different types of nervous insults. Furthermore, it has 
been shown that astrocytes are involved in the evolution of glioblastomas (Henrik Heiland 
et al., 2019). Previous collaborations between the Lim Lab and Ullian Lab developed 
methods of astrocyte formation from hiPSC’s (hAstros). They also produced iPSC-derived 
neurons (iNeurons) by introducing Neurogenin2 (NGN2) transgene to iPSCs. NGN2 





Figure 3. mBrain organoids (MBOs).  (A) Collaborations from the Lim and Ullian labs 
generated a protocol to easily forms highly uniform organoids made of astrocytes and 
neurons that can handle the further introduction of various cell types. (B) This figure shows 
organoids 24 h after generation. They begin to coalesce over a period of 24-48h depending 
on cell types added and number of cells overall added to the organoid. 
 
 
We have been able to show previously that the cell types we have generated from 
iPSC’s are similar in transcriptome as well as structure to those found in vivo. NGN2-
induced iNeurons in MBOs are functional and capable of producing action potentials and 
show high rates of synaptic activity.  
 
Figure 4. iNeurons can Fire Action Potentials. This image depicts iNeuron action 
potential generation. These neurons were integrated into the mature brain organoids. 
 
MBOs can be generated from hAstrocytes and iNeurons to match the needs of the 
assay (from a 1:1 ratio of hAstros:iNeurons to solely one cell type). MBOs are capable of 




Moving towards a more representative model of gliomas in vitro.  
Previous research from the Lim Lab utilized the MBO model in a recent study to 
identify lncGRS-1 as a glioma cell radiation sensitizer (S. J. Liu et al., 2020). 
Unfortunately, because lncGRS-1 is a primate-specific lncRNA (mice do not have a 
lncGRS-1 homolog), it is not possible to study the toxicity of lncGRS-1 knockdown in 
PDX or GEMM models. We thus augmented our previously described MBO model by 
adding glioma cells (Figure 4).  
 
Figure 5. MBO model with Glioma Cells Added. Generating organoids made of 
astrocytes, neurons, and tumor cells. Organoids are a useful platform because we can 
combine multiple cell types together, and control both the ratio of each cell type and the 
environment in which we raise these 3D models. Cerebral organoids are generated with 
glioma cells either seeded onto the organoid 24h after assembly or assembling glioma cells 
into the organoid simultaneously. (adapted from Liu, Malatesta, et. al 2020).  
 
We were able to model the infiltrative nature of human glioma over a 14- and 21-
day time course, showing that MBO’s are capable of mimicking an environment necessary 
for housing tumor growth and survival (Liu, Malatesta, et al 2020). By performing 
knockdown studies using antisense oligonucleotides (ASOs) on MBO’s containing various 
glioma cell lines, we showed that there was a synergistic effect between radiation and this 
drug target (Liu, Malatesta, et al 2020).  
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Although this model could show the impact of targeting lncGRS-1 on tumor 
burden, this model still does not fully recapitulate the actual disease environment. For 
example, the in vivo environment has low levels of growth factor, such as EGF and FGF 
(Joh et al., 1986), but tumors can thrive even at these low levels. Our currently described 
mature brain organoid model, however, involves adding a much higher dosage of growth 
factor to the organoid media in order for tumor cells to grow. By optimizing the media 
composition, we may be able to recreate a lower growth factor environment and thus 
establish a more representative 3D tissue environment in which to study glioma growth. 
Furthermore, mature brain tissue consists of more than astrocytes and neurons. While 
astrocytes and neurons present the basic neural cell types, cerebral tissue and the human 
glioma micro-environment is comprised of more. Various cell types, including microglia, 
oligodendrocytes, and endothelial cells are important in promoting a micro-environment 
that promotes tumor growth and proliferation.  
  
My first goal with this project was to focus on generating a more representative 
tumor micro-environment by manipulating the growth factor concentration in which 
tumors were growing in the MBO’s. My second goal was to focus on incorporating 
endothelial cells in these cerebral organoids because glioblastoma cells possess strong 
angiogenic properties (Bao et al., 2006) and are thus easily able to recruit blood vessel 
supply as the tumor grows.  
 
Glioma remains a fatal, yet poorly understood, disease. However, by improving 
upon the models that have helped us so far to learn about this disease, we can come closer 
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Cell Culture.  
HUVECs. Primary human umbilical vein endothelial cells (HUVECs) were ordered 
from ATCC and grown in Vascular Cell Basal Medium (ATCC Catalog # PCS-100-
030TM), supplemented with the Endothelial Cell-Growth Kit VEGF (ATCC Catalog # PCS-
100-041TM). Cells were passaged every four days and split at a 1:5 ratio. Cells were plated 
in the morning at about 60% confluence.  
SF8628 DIPG Tumor Line. SF8628 (human DIPG cell line) were grown in N5, no 
FBS (Neurobasal A, N2 supplement, B27 without Vitamin A supplement, and antimycotic-
antibiotic). Cells were passaged every four days and split at a 1:5 ratio. The cells were 
RFP-tagged via lentiviral delivery. For viral preparation, 293T cells were plated the day 
before at ~70% confluence. The following day, 1500 µl Opti-MEM was mixed with 25 µL 
of Mirus and incubated for 5 minutes at room temperature. Packaging vectors pCMV-
dR8.91 and pMD2-G were mixed with the lentiviral plasmid mScarlet-T2A-Luci and 
added to the Opti-MEM mix. Following 30 min incubation, the mixture was added gently 
to the 293T plate. After 6 hours, 24 µL of ViralBoost agent was added to the 293T plate. 
The plate was allowed to incubate for 72 h prior to harvest. On the day of harvest, the 
supernatant was filtered through a 0.4 µm filter and added to SF8628 cells for 24 h before 
full media replacement. After 72 h, regular media was added and cells were isolated with 
FACS (fluorescence-associated cell sort) for the RFP label at the Parnassus Flow 
Cytometry Core.  
	
15 
U87 cell line. U87 cells were grown in DMEM with 10% FBS and 
antibiotics/antimycotics. Cells were passaged every four days and split at a 1:5 ratio. Cells 
were plated in the morning at about 60% confluence.  
iAstrocytes. iPSCs were dissociated and reformed as embryoid bodies, and neural 
induction was initiated using 2 μM SB431542 (Catalog#722344, STEMCELL 
Technologies) and 200 nM DMH1 (Catalog#73634, STEMCELL Technologies) in defined 
media composition – DMEM/F12, GlutaMax, sodium bicarbonate, sodium pyruvate, N2, 
and B27 supplements. Neuroepithelial cells were isolated and maintained in suspension 
using media composition described above accompanied with growth factors epithelial 
growth factor (EGF) and basic fibroblast growth factor (FGF-2/FGF-2) to promote 
proliferation and astrocyte maturation.  
iNeurons. WTC11 human iPSCs were generated utilizing previously established 
protocol (Liu, Malatesta, et al 2020). Briefly, iPSCs containing doxycycline-inducible 
cassette NEUROG2 were induced into neurons following treatment with doxycycline in 
defined media – DMEM/F12, N2 supplement, non-essential amino acids, and Glutamax 
for three days.  
 
Transfection of U87 cell line. 
 Locked nucleic acids (LNA) antisense oligonucleotides (ASOs) for lncGRS-1 and 
p53 were designed using Qiagen custom LNA oligonucleotides designer. ASOs were 
transfected into U87 cells plated at 60-70% confluence at a final concentration of 50 nM 
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using Lipofectamine RNAiMAX reagent following manufacturer instructions 
(Thermofisher).  
Immunohistochemistry for P53BP1 & γ-H2AX 
Cells were plated in 8-well chambered slides (Thermo Scientific Nunc 154526) at 
a density of ~10,000 cells/cm2  and cultured overnight. Each chamber was transfected with 
either control ASO or lncGRS-1 ASO (50 nM) and then irradiated at 2 Gy. Cells were fixed 
post-6 h radiation with 4% paraformaldehyde for 15 minutes at room temperature. They 
were further incubated in permeabilization reagent (0.1% Triton-X100 in TBS (tris-
buffered saline)) for 15 minutes at room temperature. Cells were blocked in blocking 
solution (10% normal donkey serum in TBS) for 1.5 h in a humidified chamber. Cells were 
incubated in primary antibody solution anti-rabbit Phospho-53BP1 (Ser1778, Cell 
Signaling Technologies) at a 1:100 concentration and anti-rabbit γ-H2AX (Ser139, Cell 
Signaling Technologies) at a 1:400 concentration. Plates were incubated overnight at 4℃. 
Cells were washed in PBST and secondary antibody and DAPI (4’6-diamidino-2-
phenylindole) were added (Alexa 488 for P53BP1 and Alexa 594 for γ-H2AX) at a 1:1000 
concentration. Plates were incubated for 2 h at room temperature in a humidified chamber 
away from light. Slides were washed and mounted with Aqua-PolyMount. Slides were left 
to dry in the dark at room temperature for 3 hours. Images were acquired at room 
temperature on an SP3 Leica Confocal microscope using 63X oil objective and processed 





Western Blot Analysis  
One day following transfection with control ASO or lncGRS-1 ASO (50 nM), U87 
cells were lysed in RIPA buffer supplemented with HALT protease inhibitor (78429; 
ThermoFisher Scientific) following PBS washes. Lysate was then mixed at a 1:1 
concentration with 2X NuPAGE LDS (lithium dodecyl sulfate) Sample Buffer and run on 
a NuPAGE 10% Bis-Tris gel using NuPAGE MOPS (3-(N-morpholino) propanesulfonic 
acid) SDS (sodium dodecyl sulfate) Running Buffer. Proteins were then transferred from 
the gel to an Amersham Hybond PVDF (polyvinylidene fluoride) membrane using 
NuPAGE Transfer Buffer with 10% methanol for 2 h. Membrane was blocked for 1 hour 
in Odyssey Blocking Buffer and left at 4°C overnight in primary antibodies p53 (9282), 
1:500; p21 (2947), 1:1000; GAPDH_14C10(2118), 1:1000 from Cell Signaling 
Technologies and αTubulin (clone DM1A), 1:5000 from Millipore. Prior to secondary 
antibody application, cells were washed in PBS (phosphate buffered saline) + 0.1% Tween. 
Then, secondary antibodies were added (IRDye 800CW goat anti-mouse IgG (926-32210) 
and goat anti-rabbit IgG (H+L) secondary antibody, DyLight 680 (35568, 
ThermoScientific). Images were captured using LiCOR Odyssey Infrared Imaging 
Systems. Grayscale images of blots were quantified using ImageJ. 
 
EGF/FGF-2 growth factor concentrations.  
Organoid generation. Cells were grown as described above prior to organoid 
generation. iAstrocytes and iNeurons were combined at a 4:1 ratio, forming ~10,000 cells 
per organoid. SF8628 cells were added to the organoids at a 1:100 ratio. Organoids were 
prepared in a 384-well plate (Corningware Catalog #4516) and were plated in a 96-well 
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plate (Corningware Catalog #4515) 24h later, following spheroid formation. Organoids 
were imaged on a Leica DMI4000 B fluorescence microscope every other day over a 10-
day period. Images were processed using NIH ImageJ.  
 
Media Composition Optimization Experiment with endothelial-MBO’s: 
 Organoid Generation. Endothelial cells were either obtained from the Ullian lab, 
which had primarily derived endothelial cells from patient umbilical vein tissue or obtained 
from ATCC. Both were incubated in a calcein solution for 40 minutes. Calcein dye was 
used to label live cells in order to map their movement and growth over a period of time. I 
utilized this particular dye to note how long endothelial cells could survive in each media 
type. Organoids comprised of astrocytes, neurons, and either endothelial cell type were 
generated at a 4:1:1 ratio, respectively. First, single cell suspensions of each cell type were 
prepared following a trypsin wash at a concentration of 1 million cells/mL. Cells were then 
combined in a 15 mL falcon tube and added to a 384 well plate to reach a final cell count 
of 60,000 cells per organoid. Cells were added to a 384 well plate. SF8628 DIPG cells were 
added to the 384 well plate at a 1:100 ratio of DIPG cells : normal cells per well for 60 





Figure 6. MBO model with endothelial cells added. Cartoon depicting the formation of 
endothelial-MBO’s (E-MBO’s). Astrocytes, neurons, and endothelial cells were added at 
a 4:1:1 ratio, mimicking brain tissue’s normal environment, where astrocytes are the most 
abundant cell type present.   
 
 
Experimental Design. Three media conditions were used – astrosphere media 
(DMEM/F12, GlutaMAX, B27 without vitamin A, N2 supplement, Heparin, and 
antibiotic-antimycotic), cortical organoid media (DMEM/F12, NeuroBasal A, B27 without 
Vitamin A, MEM-NEAA (MEM-non-essential amino acids), GlutaMAX, Insulin solution, 
and Antibiotic-Antimycotic), and endothelial culture media (EBM2 from Lonza, 
Hydrocortisone, hFGF-B, VEGF, R3-IGF1, ascorbic acid, hEGF, GA-1000, and heparin). 
Organoids were centrifuged at 300xg for 3 minutes following and allowed to settle 
overnight. 
 One day following organoid generation, MBOs+E were moved into a 96-well ultra 
low attachment plate and centrifuged at 300xg for 3 minutes. Organoids were imaged every 
other day for 10 days on a Leica Inverted Epifluorescence Microscope for 10 days. RFP 
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signal of SF8628 cells and fluorescence signal of Calcein dye (excitation/emission 
wavelengths of 495/515 nm) was measured using ImageJ. Images were obtained from a 



































lncGRS-1 knockdown increases p21 expression and decreases p53 expression.  
 Following knockdown of lncGRS-1 in U87 GBM cells, we performed Western blot 
analysis. Based on RNA Seq analysis, we hypothesized that p21 levels would be 
upregulated while p53 would be downregulated upon knockdown (Figure 6A). The western 
blot did not show distinct enough bands for qualitative evaluation (Figure 6B), so we 
performed quantitative analysis using ImageJ. Quantification of blots (Figure 6A) was 
done by normalizing each signal intensity with corresponding loading control and 
normalizing again to average of negative control conditions. Here, we saw that p53 levels 
were decreased in knockdown condition compared to control by ~2-fold (Figure 6C). 
Qualitatively, p21 levels in the Western blot appeared to increase upon knockdown of 
lncGRS-1, compared to the control. We performed quantitative analysis to confirm this 
data (Figure 6C) and saw a 2-3 fold increase in p21 levels (Figure 6C).  These results 
validated RNA-seq analysis showing the same trend (Figure 6A).  
 
 
Figure 7. P53 levels decrease and p21 levels increase upon lncGRS-1 knockdown. 
Previously done RNA seq analysis (Liu, Malatesta et al 2020) indicates increased p21 
levels and decreased p53 levels when lncGRS-1 in U87 was knocked down with antisense 
oligonucleotides. This was in accord with qualitative and quantitative results shown in 
A B C 
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These results suggested that lncGRS-1 plays a role in cell cycle regulation, as p21 
is a well-characterized as a cell cycle exit factor (Perucca et al., 2009, p. 21).  
 
P53BP1 foci increase in response to lncGRS-1 knockdown.  
We were interested in studying the impact of this knockdown on other proteins 
involved in the p53-mediated DNA damage response. We performed a time course assay 
to find at which time nuclear foci containing these proteins were most highly evident in 
U87 cells. Cells were fixed at 4, 6, 16, and 48 h post-radiation. We observed the greatest 
number of foci by hour six in both radiation and absence of radiation conditions for 
lncGRS-1 ASO treated samples and control ASO treated samples (Figure 7).  
P53BP1, a binding protein, and p53 are required for both intra-S phase and G2-M 
checkpoints (Escribano-Díaz et al., 2013). Phosphorylation of the 53BP1 allows 
recruitment of it to double strand break sites (Rappold et al., 2001). In response to ionizing 
radiation and synthetic p53 activation, 53BP1 can stimulate genome-wide p53-dependent 
transactivation and repression (Rappold et al., 2001). We noted that knockdown of 
lncGRS-1 led to an increased amount of P53BP1 foci when compared to the negative 
control. However, irradiation of samples at 2 Gy did not significantly potentiate the effect 
of lncGRS-1 knockdown in terms of the number of P53BP1 foci (Figure 8A).  It is 
interesting to note that P53BP1, p21, and other p53 effector protein levels increase with 





Figure 8. P53BP1 and γ-H2AX protein immunohistochemistry. Left panel is a stain 
showing P53BP1 foci (in green) in response to lncGRS-1 knockdown as well as in control 
condition in presence or absence of radiation. Right panel shows same conditions, but for 
γ-H2AX foci (in red).  
 
 
γ-H2AX foci also increase in response to lncGRS-1 knockdown in the presence of 
radiation. 
We also performed immunohistochemistry to examine whether changes in γ-H2AX 
levels in response to knockdown of lncGRS-1 and radiation treatment. We performed the 
same time course assay (along with 53BP1 trial) to find the optimal time for imaging 
nuclear foci in U87 cells. We again saw greatest number of foci at hour 6 in both radiation 
and absence of radiation conditions for lncGRS-1 ASO treated samples and control ASO 
treated samples. I have shown the results collected at hour 6 here (Figure 8B).  
H2AX is a histone protein that is phosphorylated in response to DNA damage by 
kinases such as ATM or ATR as part of the PI3K pathway (Cortez et al., 2001). When 
phosphorylated, it is referred to as γ-H2AX. This begins a series of steps to recruit DNA 




while γ-H2AX foci were not increased by lncGRS-1 knockdown alone, lncGRS-1 
knockdown did potentiate the effect of radiation.    
 
Concurrent knockdown of p53 and lncGRS-1 does not rescue proliferation caused 
by lncGRS-1 knockdown.  
 In response to DNA damage, the p53 signaling pathway is quickly activated, halting 
cell cycle progression and eventually leading to cellular apoptosis (O’Connor et al., 1993). 
Single knockdown of lncGRS-1 in various glioma cell lines decreased proliferation (Liu, 
Malatesta et al 2020), suggesting that cells lacking this lncRNA have diminished cell cycle 
progression. We were interested in examining whether decreasing p53 levels 
simultaneously with lncGRS-1 knockdown by adding a condition where we treated 
samples with ASOs targeting both lncGRS-1 and p53. 
 We performed a double knockdown assay, depleting p53 and lncGRS-1 transcripts 
in U87 cells either simultaneously or separately. When combined with lncGRS-1 ASO, 
p53 knockdown strengthened the decreased proliferation response seen in lncGRS-1 ASO 
treated cells. Thus, the double knockdown did not rescue the proliferation caused by 




Figure 9. Double knockdown of lncGRS-1 and p53 decreases U87 proliferation. 
Concurrent knockdown of p53 and lncGRS-1 showed further decreased proliferation than 





















Growth factor concentration impacts the rate of tumor growth in mature brain 
organoids. 
 In previous experiments that we used MBOs, we had relied on an overall growth 
factor concentration of 20 ng/mL of EGF and FGF each. This led to rapid tumor growth in 
the organoid within 10 days, which is not likely representative of the relatively slower 
growth of glioblastomas in human patients.  Furthermore, this growth factor concentration 
is far higher than serum levels of growth factor in vivo. Therefore, we were interested to 
examine whether we could grow the SF8628 DIPG cell line in lower concentrations of 
growth factor.  
 We generated organoids made of 10,000 cells, with a 4:1 astrocyte:neuron ratio and 
1:100 ratio of DIPG:normal cells and followed their growth for ten days in 7 different 
growth factor concentrations (Figure 9A). All media compositions less than 9 ng/mL 
showed little to no tumor growth. By day 10 of the assay, tumors in the 9 ng/mL growth 
factor concentration had grown to be about half of the organoid. By day 10, tumors growing 










Next, we wanted to see if we could eliminate one growth factor entirely (Figure 
9B). Hence, we compared results between having both EGF and FGF versus only EGF. 
This experiment showed that FGF-2 is critical for tumor growth as none of the organoids 
in the EGF-only condition grew any tumors from day 0 to day 10.  
 
 
Cortical organoid media supports tumor growth in mature brain organoids. 
Organoids (MBO+E’s) made of 60,000 cells, with a 4:1:1 
astrocyte:neuron:endothelial cells ratio and 1:100 ratio of tumor cells to normal cells and 
were examined for eight days. Two different HUVEC populations were used, the first being 
A B 
Figure 10. Impact of different concentrations of EGF/FGF-2 on tumor growth. 
MBOs were placed in varying growth factor concentrations and followed for 10d to 
study impact of decreased growth factor concentrations or lack of one growth factor 
entirely. Here, I have shown day 0 (7-6-2019) in comparison with day 10 (7-18-





purchased from ATCC.org and the second being given to us from the Ullian lab, who 
derived the cell line from primary tissue. To label cells with a fluorescent dye, calcein AM 
(2 µg/mL) was added to both populations of endothelial cells prior to the assay.  
MBO+E growth was followed for eight days in three different media compositions 
(astrosphere media, cortical organoid media, and endothelial growth media 2 from Lonza), 
but kept the growth factor concentration at 10 ng/mL, based on the previous growth factor 
experiment. After day 2, the organoids were not coalescing into spheres in the endothelial 
growth media (data not shown). The other two media types allowed for the cell cultures to 
amalgamate into amorphous structures (data not shown). On day 4, the ASM- and COM-
bathed organoids had become spheroids, but the EGM2 organoids remained amorphous. 
Furthermore, tumor cells had overgrown in organoids bathed in EGM by day 4, indicating 
that this media composition was not ideal to perform longer term drug testing, such as a 
lncGRS-1 knockdown study.  
By day 8, it was clear based on the 
fluorescence signal of the calcein that the 
endothelial cells were alive in the cortical 
organoid media but were dying out in the 
astrosphere media. Although the overall signal 
had become fainter over time in the three 
media conditions due to cellular apoptosis, 
the signal in cortical organoid media and 
endothelial growth media 2 was still quantifiable. Furthermore, it appeared as though the 
Figure 11. Endothelial cell growth in 
MBOs+E cultured in astrosphere 
media. Endothelial-MBO grown in 
astrosphere media showed little to no 
green fluorescence signal by day 8. 
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other cell populations, including tumor cells, survived in cortical organoid media. There 




Figure 12. Cortical organoid media appears to support growth of multiple cell 
types in the MBO+E model. 
A) MBOs were generated containing 4 cell types (astrocytes, neurons, endothelial cells, 
and tumor cells) and followed for 8 days. Cortical organoid media proved to house all 
4 cell types for the longest, considering it possessed the greatest green fluorescence 
signal, qualitatively, of all the media compositions.  
B) MBOs were generated comprised of 3 cell types (astrocytes, neurons, and 
endothelial cells) and similar results were seen in that green fluorescence signal was 
lost the least amount in cortical organoid media by day 8.  
C) MBOs were generated consisting of 3 cell types (astrocytes, neurons, and DIPG 
cells) to follow up on how tumor cells are impacted by media type. 
All organoids were generated at a 4:1:1 astrocyte:neuron:endothelial cell ratio, and a 
1:100 glioma:normal cell ratio. Organoids were made up of 60,000 cells each, and 10 
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Endothelial cells are capable of forming tube-like structures in an in vitro 
environment.  
As a preliminary study, I wanted to assess the interactions between endothelial cells in an 
in vitro controlled environment. As a result, I performed an endothelial tube formation 
assay. I was able to see string-like projections forming by hour 4 as the cells moved 

















Figure 13. Preliminary endothelial tube formation assay. 
Endothelial tube formation assay. Figure on the left indicates hour 0 
time point, when cells had just been settled into basement membrane 
extract. Right figure is at hour 4, where we see string-like projections. 
HOUR 0 HOUR 4 





In my thesis, I had two experimental goals – 1) to focus on the role of lncGRS-1 as 
a potential therapeutic target for gliomas and, 2) to work towards improving the MBO 
models that we had been using to target this lncRNA.  
 
Project One. 
Our experiments showed that upon knockdown of lncGRS-1, there are decreased 
levels of p53 and increased levels of p21 (CDKN1A). These results implicate lncGRS-1 
having a role in cell cycle progression. Interestingly, double knockdown of lncGRS-1 and 
p53 did not rescue the cell proliferation phenotype. This could be explained because U87 
cells have been reported to have very low levels of p53 present (Badie et al., 1999), so 
further depleting p53 levels may not have led to any effect. We see damage response 
pathway proteins P53BP1 and γ-H2AX upregulated in response to regulation, and P53BP1 
presence significantly increased when radiation treatment was coupled with lncGRS-1 
knockdown.  
It is not enough to say that lncGRS-1 plays a role – to develop this genetic target as 
a potential therapy to fight human glioma, identifying the mechanistic action of lncGRS-1 
is very important. I speculate that based on our existing findings, lncGRS-1 may affect p53 
expression levels, which in turn manifests as increased apoptosis and therefore decreased 
actions of other proteins involved in this pathway. Based on double knockdown studies 
(Figure 7), it seems possible that lncGRS-1 is a promoter of p53 function. When we only 
depleted p53, we did not see as much cell death (Figure 9). When we only depleted 
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lncGRS-1, we detected a greater decreased cell proliferation than p53 knockdown alone 
shows (Fig 9).   
lncGRS-1 also seems to play a role in the DNA damage response pathway. 
Radiotherapy remains a key part of the standard of care of treatment for both adult and 
pediatric gliomas, but this therapeutic modality causes damage to the DNA of both tumor 
cells and normal brain tissue (Mladenov et al., 2013). The DNA damage response, again, 
elicits p53 function to halt further cell cycle progression to either allow cells time to repair 
DNA or push irreparably damaged cells toward apoptosis. P53 has previously been shown 
to induce lncRNA’s to impact apoptosis (Hung et al., 2011) or downregulate p53 function 
itself (Huarte et al., 2010). Previous data from the Lim Lab has shown that lncGRS-1 
knockdown results in decreased G2 and M phase in U87 populations (Liu, Malatesta et al, 
2020). This supports the hypothesis that cells lacking lncGRS-1 could have either slowed 
or diminished cell cycle progression.  
 
Future directions. A future direction, therefore, of this assay, would be to elucidate 
the mechanism of lncGRS-1 in cell cycle progression and if there is any direct effect of 
this lncRNA on p53. P53 is an important protein because it modulates the expression of 
genes necessary for DNA repair, mitosis, and apoptosis. Its inactivation or loss may be key 
to the tumorigenicity of cancers. I would introduce exogenous p53 to U87 cells and 
compare the impact of lncGRS-1 knockdown on U87 cells with native levels of p53 
expression versus with increased exogenous p53 expression. I would also perform a 
lncGRS-1 knockdown assay in glioma cells with higher native levels of p53 expression. I 
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would study the impact of depleting p21 levels in a double knockdown assay with lncGRS-
1. I postulate that double knockdown of lncGRS-1 and p21 could lead to rescued cell 
proliferation phenotype.  
Another future direction would be to perform time course RT-qPCR analysis on 
lncGRS-1 and p53 knockdown levels to optimize at which time during the double 
knockdown proliferation assay shows the greatest knockdown. I would also test different 
concentrations of the p53 ASO to find out what concentration is best to see optimal 
knockdown. Finally, I would try greater concentrations of lncGRS-1 to see at which 
concentration of this ASO is toxic for the cells.  
Identifying lncGRS-1’s role, if any, in modulating p53 expression would provide 















My second goal was to generate mature brain organoids that were more 
representative of the disease in human patients. Previous experiments from the Lim Lab 
had used mature brain organoids consisting of astrocytes, neurons, and glioma cells at fixed 
concentrations that allowed for the cells to diffuse throughout the organoid. However, the 
glioma would rapidly overtake the organoid, which is not a true representation of how 
actual gliomas progress. Hence, I wanted to assess the impact of changing both growth 
factors and media types in our MBO model to see if we could generate slower-growing 
tumors. The growth factor experiment importantly showed that reduced growth factor 
concentrations of growth factor led to slowed tumor growth, and furthermore, depriving 
tumor cells of FGF-2 led to no tumor growth whatsoever over a span of 10 days. FGF-2 is 
important to tumor cells because it promotes tumor genesis and proliferation, and has been 
suggested to be a potential biomarker for malignant cancers (M. Liu & Xing, 2017). 
However, MBOs can be cultured for several months, and it is possible that the growth of 
tumors would be evident after such prolonged periods of time.     
Cerebral organoids are a novel method of studying malignant glioma and for 
generating targeted therapies. However, MBOs can only fully represent the disease if all 
cell types are taken into account, because glioma cells likely interact in some way with all 
factors in their environment. Currently, growing HUVEC’s in vitro requires addition of 
many growth factors into the media of interest. This makes culturing the endothelial cells 
in the same media as the MBO’s challenging as one of our other future directions is to 
move away from using growth factor to sustain MBOs. When I added endothelial cells to 
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my mature brain organoids, I decided to only measure the impact of different media 
compositions on organoid formation and glioma growth, leaving the exogenous growth 
factor concentration at 10 ng/mL. Cortical organoid media appeared to be suitable to 
support all cell types tested.  The green fluorescence signal of calcein in endothelial cells 
was longest lasting in this media type, suggesting that at least some endothelial cells were 
still alive. This experiment showed me that organoids comprised of astrocytes, neurons, 
endothelial cells, and tumor cells are capable of growing in the cortical organoid media at 
a reduced growth factor concentration (10 ng/mL) than what we had been previously using 
(20 ng/mL). 
 
Future directions. Although these results are promising, the caveat here is that 
calcein fluorescence is not the most definitive method for evaluating endothelial cells 
viability. A future direction is to FACS-label endothelial cells with green fluorescent 
protein for a longer-lasting marker. I am also interested in using brain microvascular 
endothelial cells instead of HUVECs, as these are a more representative population found 
in brain tissue. After learning that organoids derived from human glioblastoma tumors can 
grow without exogenous EGF/FGF in defined media called cortical organoid media (Jacob 
et al., 2020), my next step would be to optimize this media composition further to move 
the organoids out of a reduced growth factor environment into a medium without 
exogenously added growth factors. For instance, it would be interesting to try cultivating 
primary patient-derived tumor cell lines and endothelial cell lines in media without 
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exogenous growth factor introduction. I would also attempt to grow the cell lines by slowly 
growth-factor starving them over a period of a few months.  
Another future direction would be to add more cell types into the MBO, such as 
microglia and oligodendrocytes. Microglia are immune cells in the central nervous system, 
and it is thought that they add to a supportive environment for tumor growth. RNA-Seq 
data has shown a distinct phenotype in astrocytes that engage with microglia in the tumor 
environment, leading to the release of anti-inflammatory cytokines, promoting 
immunosuppression, and thus allowing for the tumor cells to proliferate (Henrik Heiland 
et al., 2019). Oligodendrocyte progenitors and microglia have also been shown to induce 
stemness in glioma cells, which suggests that these cells are involved in creating a healthy 
tumor microenvironment (Hide et al., 2019).  
In the human body, every tissue is close to a capillary network in order to maintain 
a constant supply of oxygen and nutrients. Oxygen is important for the upkeep of oxidative 
phosphorylation, and therefore, ATP, for various cellular processes (Chance, 1965). In 
normoxic conditions, angiogenesis is prevented due to inhibition of VEGF expression by 
ubiquitination of HIF1-alpha (hypoxia inducible factor 1-alpha) by E3 von Hippel-Lindau 
(pVHL) ubiquitin ligase, promoting proteasomal degradation (Pugh & Ratcliffe, 2003). As 
a tumor grows larger, it requires an oxygen supply as well to prevent hypoxia (Semenza, 
2003), and therefore will release factors that promote angiogenesis (Lee et al., 2007). 
endothelial cells will release nitric oxide, which interacts with pVHL, a factor that prevents 
HIF-alpha from entering the nucleus in normoxic states. This allows HIF-1 alpha to enter 
the nucleus. When HIF-alpha enters the nucleus, it binds to DNA and leads to expression 
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of VEGF, which then initiates angiogenesis from endothelial cells (Makino et al., 2001). 
In the future, I would like to study the impact of hypoxia on tumor growth and angiogenesis 
in the organoids, specifically focusing on whether tube networks more readily form or form 
more quickly than in a normoxic state. I would FACS-label endothelial cells with dCas9-
KRAB and generate sgRNA’s targeting VEGF or HIF-1-alpha.  
Another future direction would be to study the impact of lncGRS-1 knockdown in 
the MBO+E model. From Liu et al 2020, organoids containing U87 cells at variable 
concentrations with either astrocytes or astrocytes and neurons were targeted with either 
radiation or ASO treatment or both, and a significant reduction in tumor burden (but not 
organoid size) was seen in response to both radiation and ASO compared to radiation alone 
(Liu, Malatesta, et al 2020). With the addition of endothelial cells, I postulate that tumors 
will grow more rapidly, so we will need to optimize the concentration of ASO to 
knockdown lncGRS-1 and decrease tumor burden.    
Generating a more representative model of glioma will allow researchers to better 
understand disease progression. It could potentially give us a means to understand the 
pathogenic drivers of glioma, because we would have the opportunity to not only study the 
molecular biology surrounding growth but also a means for studying basic tissue dynamics 
and how the microenvironment can impact how quickly the glioma worsens. Additionally, 
generating a more representative mature brain organoid might benefit research in other 




 There is a great need to find treatments for human gliomas, a fatal disease of the 
nervous system. Although current standard of care treatment such as radiation therapy, 
surgery, and chemotherapy can help mitigate the impacts of these fatal tumors, in some 
cases, such as DIPG, surgery is not possible as the tumor spreads diffusively through the 
pons. Here, radiotherapy remains the main way to treat the disease. Thus, it is important to 
find a new therapy that can potentiate the effects of current treatment standards to improve 
the prognosis of this disease. lncGRS-1 knockdown showed a decrease in glioma cell 
proliferation (Figure 9) and an increase in DNA damage response proteins (Figure 8) in 
vitro, so this lncRNA is a potentially interesting therapeutic target.  
Currently, studies in this field have relied upon 2D culture or low-throughput rodent 
studies (PDX and GEMM) to describe how gliomas develop. As we move towards 
evaluating new therapies to fight this fatal illness, these models fall short. They do not fully 
recapitulate the complex human tumor micro-environment in various ways. The mature 
brain organoid model I have developed here presents a medium-throughput means to 
accelerate the search for new therapeutics. As we continue to optimize this model by adding 
in more cell types and changing media composition to come as close as possible to in vivo 
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